Genmab

	15/5 17:49 af kkjoel	I hvert fald vel interessant at GEN har kontraktsikret førsteret for at forhandle cami 100% hjem igen. Nogen der kan sige noget om hvor normal og/eller dyrt det måtte være?
	15/5 17:44 af kkjoel	2. forekomst... henviste til at interesserede selv kunne fremsøge i nævnte securities filing.
	15/5 17:43 af kkjoel	Så gad vide om der SKAL forhandles indenfor de 65 dg fra 02.04, eller om det "partial clinical hold" (omtalt i Fiercebiotech artilen EL linkede til 17:15) gør at det hele udskydes?!
	15/5 17:39 af kkjoel	2. forekomst af "Business—License and Collaboration Agreements—Genmab Collaboration and License Agreement"
	15/5 17:38 af kkjoel	"Both parties are required to use commercially reasonable efforts to complete and maximize the value obtained in this process. Therefore, our rights to Cami are subject to our collaboration and license agreement with Genmab, and there can be no assurance that we will apply for regulatory approval of or commercialize Cami."
	15/5 17:38 af kkjoel	"See “Business—License and Collaboration Agreements—Genmab Collaboration and License Agreement.” The agreement sets out a defined process to facilitate the divestment of Cami by licensing the rights thereto to a third party, subject to Genmab’s right of first opportunity to negotiate to acquire Cami in full. This process includes the opportunity for both parties to bid for the license rights alongside third parties."
	15/5 17:37 af kkjoel	"Risks Related to Our Relationship with Third Parties / Our rights to Cami are subject to our collaboration and license agreement with Genmab, and there can be no assurance that we will maintain the rights to develop or commercialize Cami. / Our collaboration and license agreement with Genmab requires a divestment of Cami, in which Genmab has a 25% interest, following 60 days, and no later than 65 days, after the database lock for the Phase 1/2 clinical trial, which occurred on April 2, 2020."
	15/5 17:35 af kkjoel	Fandt nedenståen i securities filingen fra ADC - ikke uinteressant vist, der blev talt om det herinde for nylig (GENs mulighed for at forhandle de 25%). (link)
	15/5 17:19 af kkjoel	Tak EL. Rart med opsummering af mAb feltet/stofferne indenfor MM.. for os der ikke er helt stive i det hele :-)
	15/5 17:15 af E L	(link) this has a bit more on Cami
	15/5 17:03 af Solsen	ADCs IPO i $19 (link)
	15/5 16:14 af E L	Educational theme \| Monoclonal antibodies for the treatment of multiple myeloma (link)
	15/5 16:08 af Bulder	Tak sukker. Rart med samling på tingene :-)
	15/5 15:45 af Sukkeralf	(link)
	15/5 15:45 af Sukkeralf	CD20/CD3 - måske postet før:
	15/5 14:13 af E L	@Mohty_EBMT presented an argument FOR the integration of anti-CD38 antibodies into induction therapies. (link)
	15/5 13:42 af E L	a few abstracts on BMS-986253 at ASCO (talking about something where i think there is not much to look forward to lol) (link)
	15/5 13:38 af E L	they did double the enrollment size not too long ago though on the -178 , that actually gave me little bit more hope ;)
	15/5 13:28 af Sukkeralf	Its funny they promote these newer DuoBodies - not much we hear about JNJ-63709178. 1 or 2 clinical holds so maybe not much to look forward to here
	15/5 13:26 af Sukkeralf	i dont think so
	15/5 12:52 af E L	haven't heard much about the CD33xCD3 duobody yet
	15/5 12:51 af E L	JNJ-67571244: A novel anti-CD33 C2 domain binding bispecific antibody with potent T cell redirection activity (link)
	15/5 12:25 af E L	JNJ-61186372, an Fc enhanced EGFR/cMet bispecific antibody, mediates EGFR and cMet downmodulation and therapeutic efficacy preclinically through monocyte / macrophage mediated trogocytosis (link)
	15/5 12:13 af E L	JNJ-61186372, an EGFR-cMet bispecific antibody, in EGFR Exon 20 insertion-driven advanced non-small cell lung cancer (NSCLC) (link)

	15/5 11:54 af E L	4544 / 12 - Multifaceted mechanism of action of DuoHexaBody-CD37 involves both complement- and Fc gamma receptor-mediated cytotoxicity in pre-clinical B-cell lymphoma models (link)
	15/5 10:45 af Solsen	Nice to hear :-)
	15/5 09:17 af E L	Someone that knows him told me that, as nice as he is, he is actually a very very tough negotiator ...
	15/5 09:16 af E L	I hope you are right on the epco deal for ASCO, but i am not sure Jan will feel much pressure ; we have been waiting soooo long; better get it right now...
	15/5 09:12 af E L	it is possible, submission deadline for late breaker for EHA is about a month later i believe
	15/5 09:08 af Sukkeralf	Could we get phase III data in amyloidosis with sc dara as a late breaker at EHA instead of ASCO?
	15/5 09:04 af Sukkeralf	or maybe even in the ASCO weekend
	15/5 09:02 af Sukkeralf	I still hope we will get that epcorita mab deal before ASCO - so my guess is either this weekend or next weekend. I would be nice to get that extra attention at ASCO. Maybe even more important in these Corona times so Genmab and Partner can keep this project moving as fast as possible
	15/5 08:40 af E L	Daratumumab treatment in heavely pre-treated immunoglobulin light chain amyloidosis (link)
	15/5 07:19 af bibob	(link)
	15/5 07:15 af bibob	ASCO: J&J 's anti - BCMA CAR-T improving with time sweeps Multiple Myeloma aside. (link)
	15/5 07:05 af bibob	GMAB US. Luk i 28,59 $. = 1981,28 kurs 6,93 $ :-)
	15/5 07:01 af bibob	God morgen. :-)
	15/5 06:11 af Plimsoller	God morgen :-)
	15/5 01:46 af gentogen	Inspireret af EL 20:14 tjekkede jeg lige igen. 2796811. Det er ganske pænt...
	15/5 00:19 af sponsor	Så kom da med den fredagsnyhed , så vi kan få skiftet sokker! ;-)
	14/5 23:04 af bikube	Kommer der også milestone til Gen.
	14/5 23:03 af bikube	Halozyme får $15M i milestone for første salg af Dara sc fra Janssen, siger Seeking.
	14/5 22:00 af Solsen	Legend IPO (link)
	14/5 21:40 af Parasitism	Der er bare nogen, som har glemt at informere Halo om at USA er i plus ????
	14/5 21:16 af Sukkeralf	(link)
	14/5 20:16 af Darvin	US vender også som “ventet” efter 2,5 dag :-)
	14/5 20:14 af E L	second day of over 2 mio ADS in the US
	14/5 20:05 af Solsen	Just like waiting for christmas. Not many days before we se the partner.
	14/5 18:32 af E L	some notable Asco presentations; includes epco (link)
	14/5 18:21 af E L	;-)